VYNE VYNE Therapeutics Inc.

Nasdaq vynetherapeutics.com


$ 0.39 $ 0.00 (0 %)    

Wednesday, 15-Oct-2025 10:50:38 EDT
QQQ $ 605.88 $ 2.06 (0.34 %)
DIA $ 465.52 $ 0.88 (0.19 %)
SPY $ 668.72 $ 1.92 (0.29 %)
TLT $ 91.14 $ 0.16 (0.18 %)
GLD $ 386.37 $ 0.43 (0.11 %)
$ 0.39
$ 0.39
$ 0.39 x 100
$ 0.39 x 200
$ 0.39 - $ 0.41
$ 0.28 - $ 4.30
2,912,926
na
9.93M
$ 1.58
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-06-2025 01-01-1970 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-01-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-14-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-17-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-04-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 03-03-2020 12-31-2019 10-K
24 10-31-2019 09-30-2019 10-Q
25 08-01-2019 06-30-2019 10-Q
26 05-02-2019 03-31-2019 10-Q
27 02-28-2019 12-31-2018 10-K
28 11-07-2018 09-30-2018 10-Q
29 08-01-2018 06-30-2018 10-Q
30 05-09-2018 03-31-2018 10-Q
31 03-28-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 vyne-therapeutics-q2-eps-013-beats-022-estimate-sales-69000k-miss-150000k-estimate

VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0...

 hc-wainwright--co-downgrades-vyne-therapeutics-to-neutral

HC Wainwright & Co. analyst Joseph Pantginis downgrades VYNE Therapeutics (NASDAQ:VYNE) from Buy to Neutral.

 vyne-therapeutics-announces-phase-2b-trial-with-repibresib-gel-in-nonsegmental-vitiligo-did-not-meet-primary-endpoint-or-key-secondary-endpoint-of-f-vasi50-and-f-vasi75

Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75Nominally Statistically Significant Effec...

 vyne-therapeutics-issues-program-update-for-vyn202-following-clinical-hold-issued-by-fda-in-april-for-phase-1b-clinical-trial-in-treatment-of-moderate-to-severe-plaque-psoriasis

VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focu...

 vyne-therapeutics-q1-eps-020-beats-029-estimate-sales-20200k-beat-5000k-estimate

VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0...

 fda-puts-vyne-therapeutics-early-stage-psoriasis-study-on-hold

VYNE pauses VYN202 psoriasis trial after FDA clinical hold tied to animal toxicity data; separate vitiligo trial remains on tra...

 hc-wainwright--co-maintains-buy-on-vyne-therapeutics-lowers-price-target-to-45

HC Wainwright & Co. analyst Joseph Pantginis maintains VYNE Therapeutics (NASDAQ:VYNE) with a Buy and lowers the price t...

 fda-places-clinical-hold-on-vyne-therapeutics-phase-1b-study-for-vyn202-following-safety-concerns

BRIDGEWATER, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company&...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION